429 related articles for article (PubMed ID: 33952676)
1. RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.
Mukherjee J; Pandita A; Kamalakar C; Johannessen TC; Ohba S; Tang Y; Dalle-Ore CL; Bjerkvig R; Pieper RO
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952676
[TBL] [Abstract][Full Text] [Related]
2. PARP1 Is a TRF2-associated poly(ADP-ribose)polymerase and protects eroded telomeres.
Gomez M; Wu J; Schreiber V; Dunlap J; Dantzer F; Wang Y; Liu Y
Mol Biol Cell; 2006 Apr; 17(4):1686-96. PubMed ID: 16436506
[TBL] [Abstract][Full Text] [Related]
3. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
[TBL] [Abstract][Full Text] [Related]
4. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
5. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
6. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
7. MRE11 and UBR5 Co-Operate to Suppress RNF168-Mediated Fusion of Dysfunctional Telomeres.
Tang Y; Mukherjee J; Pieper RO
Front Oncol; 2021; 11():772233. PubMed ID: 34881184
[TBL] [Abstract][Full Text] [Related]
8. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
9. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA.
Langelier MF; Lin X; Zha S; Pascal JM
Sci Adv; 2023 Mar; 9(12):eadf7175. PubMed ID: 36961901
[TBL] [Abstract][Full Text] [Related]
10. Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2.
Dantzer F; Giraud-Panis MJ; Jaco I; Amé JC; Schultz I; Blasco M; Koering CE; Gilson E; Ménissier-de Murcia J; de Murcia G; Schreiber V
Mol Cell Biol; 2004 Feb; 24(4):1595-607. PubMed ID: 14749375
[TBL] [Abstract][Full Text] [Related]
11. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
12. c-Myc quadruplex-forming sequence Pu-27 induces extensive damage in both telomeric and nontelomeric regions of DNA.
Islam MA; Thomas SD; Murty VV; Sedoris KJ; Miller DM
J Biol Chem; 2014 Mar; 289(12):8521-31. PubMed ID: 24464582
[TBL] [Abstract][Full Text] [Related]
13. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
14. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
15. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles for MRE11 at uncapped telomeres.
Deng Y; Guo X; Ferguson DO; Chang S
Nature; 2009 Aug; 460(7257):914-8. PubMed ID: 19633651
[TBL] [Abstract][Full Text] [Related]
17. Both the classical and alternative non-homologous end joining pathways contribute to the fusion of drastically shortened telomeres induced by TRF2 overexpression.
Nera B; Huang HS; Hendrickson EA; Xu L
Cell Cycle; 2019 Apr; 18(8):880-888. PubMed ID: 30907229
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
19. Telomere length modulation in human astroglial brain tumors.
La Torre D; Conti A; Aguennouz MH; De Pasquale MG; Romeo S; Angileri FF; Cardali S; Tomasello C; Alafaci C; Germanò A
PLoS One; 2013; 8(5):e64296. PubMed ID: 23691191
[TBL] [Abstract][Full Text] [Related]
20. PRDX1 Counteracts Catastrophic Telomeric Cleavage Events That Are Triggered by DNA Repair Activities Post Oxidative Damage.
Ahmed W; Lingner J
Cell Rep; 2020 Nov; 33(5):108347. PubMed ID: 33147465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
